TB-500 is a fragment of thymosin beta-4, the protein tested in trials

What is the difference between TB-500 and thymosin beta-4?

Thymosin beta-4 is a 43-amino-acid protein whose primary job in cells is sequestering unpolymerized actin monomers ^[6]. TB-500 is the name attached in commercial contexts to a much shorter fragment built from a portion of that same protein's actin-binding sequence.

Thymosin beta-4 has been studied as a synthetic and recombinant compound in animal biodistribution work ^[6] and in a run of small human trials covering cardiac, ophthalmic, and wound-healing applications ^[1]⁠^[2]⁠^[3]⁠^[4]⁠^[5]⁠^[7]. No trial in that literature tests the fragment in humans.

The full protein and the fragment are not interchangeable products. They are two different peptide chains. The human evidence for the TB-500 fragment stands on its own much shorter record.

How can a buyer tell TB-500 from thymosin beta-4?

Molecular weight distinguishes them, and it is the one objective, checkable fact a buyer has access to. A full protein and a short peptide fragment differ enormously in molecular weight, typically several thousand daltons for the full protein versus a small fraction of that for a short fragment. Those figures come from general peptide chemistry rather than from any of the trials below, so they are background rather than study findings.

The molecular weight line on a certificate of analysis is a testable, physical property. Purity percentage is not a test of identity at all, and a high purity figure can still describe the wrong molecule. The guide to reading a peptide COA covers which fields carry that information.

What human trials has thymosin beta-4 been through?

Thymosin beta-4's human evidence is real but narrow, and it belongs entirely to the full-length protein. Two Phase 1 trials established tolerability rather than efficacy.

A first-in-human Phase 1 trial gave 54 healthy volunteers ascending intravenous doses of recombinant human Tβ4, from 0.05 to 25.0 μg/kg as a single dose, then daily dosing for 10 days at up to 5.0 μg/kg. Adverse events were mild to moderate with no dose-limiting toxicities ^[1]. A separate Phase 1 trial using synthetic intravenous Tβ4 in 40 healthy subjects reported a similar safety profile with no dose-limiting toxicity across its dose range ^[4].

Neither trial established that Tβ4 treats or cures anything. They established that it was tolerated at the doses tested, the correct first question for any injectable.

What results did thymosin beta-4 produce beyond safety?

A small Phase 2 trial of Tβ4 eye drops in 9 patients with severe dry eye found statistically significant improvements in ocular discomfort and corneal staining scores at day 56 versus vehicle control ^[2].

Topical Tβ4 has also been studied in venous ulcers in European dose-escalation trials with tens of patients, which described an acceptable safety profile and a healing rate in a subset of milder wounds ^[3]⁠^[5]. Animal work has shown cardioprotective signaling changes with recombinant human Tβ4 in ischemia-reperfusion models, with an accompanying small clinical component in STEMI patients ^[7]. A pediatric cardiac surgery protocol has been proposed, which is a trial design rather than completed outcome data ^[8].

Every one of those studies used a defined, manufactured, quality-controlled version of the full-length protein, delivered intravenously, topically, or as an ophthalmic solution under clinical trial conditions. None used the short fragment sold as TB-500, and none resembles a self-administered subcutaneous injection from an unlabeled vial. The gap between a controlled compound studied in a trial and an uncontrolled compound shipped to a door is the one most consumer content erases.

What does a certificate of analysis actually prove?

A COA answers one narrow question: whether the sample submitted for testing contains a high percentage of the substance the lab was told to look for.

A COA does not establish that the vial received matches the vial tested, that the synthesis produced the labeled sequence rather than a shorter or truncated version, or that nothing else is present, including residual solvents or endotoxin. No regulatory body verifies synthesis or vial-filling for peptides sold as research use only, so every step between raw synthesis and the vial in a buyer's hand happens without a mandatory outside check.

The controlled trials used compounds manufactured and verified under investigational protocols, because uncontrolled synthesis carries risks a purity percentage cannot rule out ^[1]⁠^[4]. That contrast is the practical reason a purity number and a certificate of authenticity are not the same document. Mislabeled or off-target vials are a known category of risk in the broader unregulated peptide market, separate from anything the trials measured. Reading peptide product documentation closely is the only check a buyer controls.

Do thymosin beta-4 trial doses apply to TB-500?

No. The Tβ4 trial doses used tightly controlled intravenous or topical delivery at microgram-per-kilogram or milligram-scale doses under medical supervision ^[1]⁠^[4].

Those doses do not transfer to a self-injected fragment product of unverified identity and unknown concentration. The fragment is a different molecule, delivered by a different route, at an unverified concentration.

What is still unknown about TB-500?

Whether TB-500 behaves like full-length Tβ4 in humans is unestablished, because the fragment has not been through the human testing the full protein has ^[1]⁠^[2]⁠^[3]⁠^[4]⁠^[5]⁠^[7]. The specific gaps:

• Human testing. No trial shows that the short fragment reproduces full-length Tβ4's effects in people.
• Dose and safety margin. Neither has been established for the fragment at any dose.
• Vial contents. No independent chain-of-custody testing accompanies most vials sold this way, so a reader at 11 p.m. has no reliable way to know what is in the vial from a vendor document alone.